FOLLICULAR NHL IN TREATMENT WITH R-CHOP AND RITUXIMAB FOR MAINTENANCE, OUR EXPERIENCE

被引:0
|
作者
Nadal Paula, Ortega [1 ]
Jose David, Gonzalez San Miguel [1 ]
Khoury Cristina, Romero [1 ]
Mesa Susej, Guedes [1 ]
Maria del Carmen, Losada Castillo [1 ]
Martin Manuel, Tapia [1 ]
Fuertes Fernando, Fernandez [1 ]
Quintana Cristina, Lemes [1 ]
Ruiz Ylenia, Morales [1 ]
Jose Miguel, Bosch Benitez [1 ]
Gomez Mar, Caballero [1 ]
机构
[1] Complejo Hosp Univ Insular Materno Infantil, Las Palmas Gran Canaria, Spain
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PO-239
引用
收藏
页码:297 / 298
页数:2
相关论文
共 50 条
  • [41] Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-NHL: 7-year follow-up results
    Itoh, K.
    Igarashi, T.
    Ogura, M.
    Morishima, Y.
    Hotta, T.
    Kinoshita, T.
    Ohashi, Y.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2
    Shu Liu
    He Huang
    Rong-xin Chen
    Zhao Wang
    Yan-ping Guan
    Chen Peng
    Xiao-jie Fang
    Zhuo-jia Chen
    Shao-xing Guan
    Xia Zhu
    Quan-guang Ren
    Yu-yi Yao
    Hong-bing Huang
    Min Huang
    Xue-ding Wang
    Tong-yu Lin
    Acta Pharmacologica Sinica, 2021, 42 : 641 - 647
  • [43] Comparison of treatment outcome of NHL-BFM-90/95 and CHOP/R-CHOP regimen for children and adolescents with diffuse large B cell lymphoma
    Sun, Fei-Fei
    Zhen, Zi-Jun
    Zhu, Jia
    Lu, Su-Ying
    Wang, Juan
    Li, Peng-Fei
    Liao, Ru
    Huang, Hui-Qiang
    Xia, Zhong-Jun
    Sun, Xiao-Fei
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 61 - 61
  • [44] Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP)
    Strati, Paolo
    Romaguera, Jorge Enrique
    Kwak, Larry W.
    Hagemeister, Fredrick B.
    Rodriguez, Maria Alma
    Oki, Yasuhiro
    Westin, Jason R.
    Turturro, Francesco
    Overman, Michael J.
    Neelapu, Sattva S.
    Fowler, Nathan
    Fayad, Luis
    BLOOD, 2013, 122 (21)
  • [45] R-Dhaox, high dose chemotherapy (HDC) and rituximab maintenance as salvage treatment in relapsed/refractory (R/R) follicular (F) and mantle cells (MC) lymphomas (NHL)
    Rupolo, M.
    Michieli, M.
    Spina, M.
    Bulian, P.
    Degan, M.
    Mazzucato, M.
    Abbruzzese, L.
    Tirelli, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment of primary gastrointestinal B-cell lymphoma
    Aguiar Bujanda, D.
    Cabrera Suarez, M. A.
    Llorca Martinez, I.
    Bohn Sarmiento, U.
    Saura Grau, S.
    Rodriguez Franco, C.
    Aguiar Morales, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)
    Strati, Paolo
    Romaguera, Jorge E.
    Kwak, Larry W.
    Hagemeister, Fredrick B.
    Rodriguez, Alma
    Oki, Yasuhiro
    Westin, Jason
    Turturro, Francesco
    Overman, Michael J.
    Neelapu, Sattva S.
    Fowler, Nathan
    Fayad, Luis
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S145 - S146
  • [49] Lenalidomide In Combination With R-CHOP (R2-CHOP) In Patients With High Burden Follicular Lymphoma: Phase 2 Study
    Tilly, Herve
    Morschhauser, Franck
    Casasnovas, Olivier
    Molina, Thierry Jo
    Mounier, Nicolas
    Salles, Gilles Andre
    Le Gouill, Steven
    Bologna, Serge
    Tournilhac, Olivier
    Cabecadas, Jose
    Bouabdallah, Reda
    Gabarre, Jean
    Lamy, Thierry
    Haioun, Corinne
    BLOOD, 2013, 122 (21)
  • [50] R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature
    Ganguly Siddhartha
    Patel Vijay
    Journal of Hematology & Oncology, 2